News Topic - Bristol-Myers Squibb
Articles 1 - 10 of most recent articles
Alabama settles suits against 5 drug companies
Associated Press - October 10, 2008 3:43 PM ET MONTGOMERY, Ala. (AP) - The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four...
LocalNews8.com – Oct 10, 2008 7:44 PM [GMT] – comment?
found in Local: Idaho: Idaho Falls
Associated Press - October 10, 2008 3:43 PM ET MONTGOMERY, Ala. (AP) - The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four...
LocalNews8.com – Oct 10, 2008 7:44 PM [GMT] – comment?
found in Local: Idaho: Idaho Falls
4-Star Stocks Poised to Pop: Bristol-Myers Squibb
Market-trouncing returns could be written in these four stars.
Fool.com – Oct 8, 2008 5:52 PM [GMT] – comment?
found in Business: Personal Finance
Market-trouncing returns could be written in these four stars.
Fool.com – Oct 8, 2008 5:52 PM [GMT] – comment?
found in Business: Personal Finance
FDA Approved Use Of REYATAZ (R) Boosted With Ritonavir, In Combination Therapy, For Previously Untreated HIV-1 Infected Adult Patients
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ® (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected ... more »
Medical News Today – Oct 8, 2008 3:00 PM [GMT] – comment?
found in Health: AIDS - HIV
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ® (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected ... more »
Medical News Today – Oct 8, 2008 3:00 PM [GMT] – comment?
found in Health: AIDS - HIV
Biotech Stocks: Bristol-Myers, Lilly lead drug stocks rebound
Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off.
MarketWatch.com – Oct 7, 2008 2:33 PM [GMT] – comment?
found in Business
Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off.
MarketWatch.com – Oct 7, 2008 2:33 PM [GMT] – comment?
found in Business
Bristol-Myers, Lilly lead rebound in drug stocks
BOSTON (MarketWatch) -- Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off. The Amex Pharmaceutical Index rose 1.7% to 282.93 and the Amex Biotechnology Index advanced 1% to 705.76. Shares ... more »
MarketWatch.com – Oct 7, 2008 1:55 PM [GMT] – comment?
found in Business: Markets
BOSTON (MarketWatch) -- Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off. The Amex Pharmaceutical Index rose 1.7% to 282.93 and the Amex Biotechnology Index advanced 1% to 705.76. Shares ... more »
MarketWatch.com – Oct 7, 2008 1:55 PM [GMT] – comment?
found in Business: Markets
Lilly to buy ImClone for $6.5 billion
The bid by Lilly for the biotechnology company beat out an offer from Bristol-Myers Squibb, which markets ImClone's cancer drug Erbitux in the United States along with ImClone.
International Herald Tribune – Oct 7, 2008 12:26 AM [GMT] – comment?
found in Business
The bid by Lilly for the biotechnology company beat out an offer from Bristol-Myers Squibb, which markets ImClone's cancer drug Erbitux in the United States along with ImClone.
International Herald Tribune – Oct 7, 2008 12:26 AM [GMT] – comment?
found in Business
Eli Lilly bids $6.5 billion for ImCloneReuters - Eli Lilly and Co has agreed to acquire ImClone Systems Inc for $6.5 billion, outbidding Bristol-Myers Squibb Co and potentially bringing to a close one of the most colorful corporate sagas in biotech history.
Yahoo! – Oct 6, 2008 10:33 PM [GMT] – comment?
found in Top Stories
Eli Lilly to buy ImClone for more than $6B
INDIANAPOLIS (AP) -- Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co....
AP – Oct 6, 2008 4:47 PM [GMT] – comment?
found in Business
INDIANAPOLIS (AP) -- Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co....
AP – Oct 6, 2008 4:47 PM [GMT] – comment?
found in Business
Bristol-Myers won't raise bid for ImClone
BOSTON (MarketWatch) -- Bristol-Myers Squibb said Monday that it will not raise its $62 as share bid for ImClone Systems , in which it already holds a 16.6% stake, adding that raising the bid was not in the best interest of its shareholders. Earlier Monday, Eli Lilly & Co. announced that it pla ... more »
MarketWatch.com – Oct 6, 2008 3:48 PM [GMT] – comment?
found in Business: Markets
BOSTON (MarketWatch) -- Bristol-Myers Squibb said Monday that it will not raise its $62 as share bid for ImClone Systems , in which it already holds a 16.6% stake, adding that raising the bid was not in the best interest of its shareholders. Earlier Monday, Eli Lilly & Co. announced that it pla ... more »
MarketWatch.com – Oct 6, 2008 3:48 PM [GMT] – comment?
found in Business: Markets
Drug stocks retreat; Lilly falls on ImClone bid
BOSTON (MarketWatch) -- Drug stocks were in retreat early Monday, following the broader market southward as European governments moved to shore up many of their leading banking institutions in the wake of a global credit crisis. The Amex Pharmaceutical Index declined 1% to 286.69 and the Amex Biotec ... more »
MarketWatch.com – Oct 6, 2008 1:50 PM [GMT] – comment?
found in Business: Markets
BOSTON (MarketWatch) -- Drug stocks were in retreat early Monday, following the broader market southward as European governments moved to shore up many of their leading banking institutions in the wake of a global credit crisis. The Amex Pharmaceutical Index declined 1% to 286.69 and the Amex Biotec ... more »
MarketWatch.com – Oct 6, 2008 1:50 PM [GMT] – comment?
found in Business: Markets